论文部分内容阅读
目的:探讨铝碳酸镁与莫沙必利对胆汁反流性胃炎的疗效及胃内胆汁的影响。方法:55例胆汁反流性胃炎患者随机分为3组。A组20例,予以莫沙必利5 mg,3次/天,治疗4周;B组15例,予以铝碳酸镁1.0 g,3次/天,治疗4周;C组20例,予以多莫沙必利5 mg,3次/天及铝碳酸镁1.0 g,3次/天治疗4周。分别于治疗前及治疗4周后观察3组患者腹胀、上腹痛、恶心及呕吐症状变化,所有患者复查胃镜。结果:治疗后3组患者症状均明显减轻(P<0.05),莫沙必利对患者腹胀、上腹痛、恶心及呕吐的总有效率分别为85.0%,66.7%,84.6%及87.5%;铝碳酸镁组分别为60.0%,80.0%,83.3%及100.0%;莫沙必利联合铝碳酸镁组分别为88.9%,82.4%,83.3%及100.0%。但各组间症状有效率的比较差异无显著性。内镜下胆汁反流减少,消失率分别为85%、90%和95%。结论:铝碳酸镁和莫沙必利合用能有效治疗胆汁反流性胃炎。
Objective: To investigate the therapeutic effect of magnesium aluminum carbonate and mosapride on bile reflux gastritis and the effect of intragastric bile. Methods: 55 cases of bile reflux gastritis were randomly divided into three groups. A group of 20 cases, to be mosapride 5 mg, 3 times / day for 4 weeks; B group of 15 cases, to be magnesium aluminum carbonate 1.0 g, 3 times / day for 4 weeks; C group of 20 cases, Mosapride 5 mg, 3 times a day and aluminum magnesium carbonate 1.0 g, 3 times / day for 4 weeks. Respectively before treatment and after 4 weeks of treatment were observed in 3 groups of patients with abdominal distension, abdominal pain, nausea and vomiting changes in symptoms, all patients underwent gastroscopy. Results: After treatment, the symptoms of the three groups were significantly relieved (P <0.05). The total effective rates of mosapride on patients with abdominal distension, upper abdominal pain, nausea and vomiting were 85.0%, 66.7%, 84.6% and 87.5%, respectively. The magnesium carbonate groups were 60.0%, 80.0%, 83.3% and 100.0%, respectively; the groups of mosapride and aluminum magnesium carbonate were 88.9%, 82.4%, 83.3% and 100.0% respectively. However, there was no significant difference in the effective rates of symptoms between groups. Endoscopic bile reflux decreased, the disappearance rates were 85%, 90% and 95%. Conclusion: The combination of magnesium aluminum carbonate and mosapride can effectively treat bile reflux gastritis.